Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Fast

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|December 22, 1998
Preventing discrimination against volunteers in prophylactic HIV vaccine trials: lessons from a phase II trialA R Sheon, L Wagner, M J McElrath, et al.
Journal of Pharmaceutical Sciences|January 20, 2011
Histamine release associated with intravenous delivery of a fluorocarbon-based sevoflurane emulsion in caninesRebecca A Johnson, Ken T Simmons, Jonathan P Fast, et al.
Sexually Transmitted Infections|March 3, 2016
Heterogeneity of HIV incidence: a comparative analysis between fishing communities and in a neighbouring rural general population, Uganda, and implications for HIV controlA Kamali, R N Nsubuga, E Ruzagira, et al.
Vaccine|April 20, 2001
A Phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjectsJ S Lambert, M Keefer, M J Mulligan, et al.
East African Medical Journal|June 8, 2011
Pregnancy rates among female participants in phase I and phase IIA AIDS vaccine clinical trials in KenyaW G Jaoko, H Ogutu, S Wakasiaka, et al.
AIDS Research and Human Retroviruses|October 6, 1997
Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation GroupM C Keefer, M Wolff, G J Gorse, et al.
AIDS Research and Human Retroviruses|June 30, 2000
A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation GroupM J McElrath, L Corey, D Montefiori, et al.
The Journal of Infectious Diseases|July 9, 1999
A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteersT G Evans, M C Keefer, K J Weinhold, et al.
Vaccine|September 25, 2008
Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteersA Guimarães-Walker, N Mackie, S McCormack, et al.
Virus Evolution|August 29, 2017
A35 Viral evolution and innate immune responses during acute HIV-1 infection and their association with disease pathogenesisA S Hassan, J Hare, G Kamini, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|December 22, 1998
Preventing discrimination against volunteers in prophylactic HIV vaccine trials: lessons from a phase II trialA R Sheon, L Wagner, M J McElrath, et al.
Journal of Pharmaceutical Sciences|January 20, 2011
Histamine release associated with intravenous delivery of a fluorocarbon-based sevoflurane emulsion in caninesRebecca A Johnson, Ken T Simmons, Jonathan P Fast, et al.
Sexually Transmitted Infections|March 3, 2016
Heterogeneity of HIV incidence: a comparative analysis between fishing communities and in a neighbouring rural general population, Uganda, and implications for HIV controlA Kamali, R N Nsubuga, E Ruzagira, et al.
Vaccine|April 20, 2001
A Phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjectsJ S Lambert, M Keefer, M J Mulligan, et al.
East African Medical Journal|June 8, 2011
Pregnancy rates among female participants in phase I and phase IIA AIDS vaccine clinical trials in KenyaW G Jaoko, H Ogutu, S Wakasiaka, et al.
AIDS Research and Human Retroviruses|October 6, 1997
Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation GroupM C Keefer, M Wolff, G J Gorse, et al.
AIDS Research and Human Retroviruses|June 30, 2000
A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation GroupM J McElrath, L Corey, D Montefiori, et al.
The Journal of Infectious Diseases|July 9, 1999
A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteersT G Evans, M C Keefer, K J Weinhold, et al.
Vaccine|September 25, 2008
Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteersA Guimarães-Walker, N Mackie, S McCormack, et al.
Virus Evolution|August 29, 2017
A35 Viral evolution and innate immune responses during acute HIV-1 infection and their association with disease pathogenesisA S Hassan, J Hare, G Kamini, et al.
Pageof 3